Atropos Health is advancing precision medicine in oncology and rare disease care with the publication of new AI algorithms for paroxysmal nocturnal hemoglobinuria (PNH) and the integration of American Society of Clinical Oncology (ASCO) clinical practice guidelines into its platform. The company, a leader in transforming real-world clinical data into personalized real-world evidence (RWE), has developed additional AI models to monitor disease progression in patients already diagnosed with PNH, a rare and serious blood disorder. These tools are designed to help reduce the risk of severe complications such as thrombosis, organ dysfunction, anemia, and worsening hemolytic anemia. The new AI models build on a previously published algorithm that improves early diagnosis of PNH. Now available for use by health systems, they enable more proactive and precise management of the disease, supporting better long-term outcomes for patients. Dr. Sandeep Jain, Director of Medical Innovation in Hematology & Oncology at Atropos Health, will present findings on the use of machine learning to identify patients likely to benefit from PNH workup at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. The presentation, titled “Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data,” will be featured in the “Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II” session on December 7, 2025, from 6:00 PM to 8:00 PM in room OCCC – West Halls B3-B4. In addition to the new AI tools, Atropos Health is integrating ASCO Guidelines directly into its platform. This integration provides oncologists and researchers with immediate access to evidence-based treatment and care recommendations, enabling more informed, personalized decision-making. The move supports the company’s mission to bring the latest clinical guidance into the workflow of healthcare providers. “The future of evidence-based medicine in oncology is being transformed by data and technology,” said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. “With the integration of gold-standard ASCO Guidelines and the publication of these new AI models, we are accelerating the advancement of precision medicine. By making these tools publicly available and embedding them within our platform, we are empowering clinicians to navigate complex patient journeys with greater clarity and deliver care that is both personalized and grounded in the best available evidence.” The announcement follows the recent launch of the Atropos Evidence™ Agent, an expert system designed to generate real-world evidence on demand. Atropos Health is now piloting the integration of this agent with Stanford Health Care, using data from ChatEHR to deliver personalized RWE directly at the point of care. In collaboration with Microsoft, the company is also combining ambient encounter data from Dragon Copilot with the Atropos Evidence™ Agent to further enhance clinical insights. Atropos Health, developer of GENEVA OS®, the operating system for rapid healthcare evidence, partners with healthcare and life science organizations to close evidence gaps from research to bedside. The company is committed to improving patient outcomes, accelerating medical research, and transforming healthcare through timely, relevant, and data-driven real-world evidence. For more information, visit www.atroposhealth.com, connect on LinkedIn, or follow @AtroposHealth on X.